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Lynch syndrome (clinically referred to as HNPCC – Hereditary Non-Polyposis Colorectal Cancer) is a frequent,
autosomal, dominantly-inherited cancer predisposition syndrome caused by various germline alterations that affect
DNA mismatch repair genes, mainly MLH1 and MSH2. Patients inheriting this predisposition are susceptible to
colorectal, endometrial and other extracolonic tumors. It has recently been shown that germline deletions of the
last few exons of the EPCAM gene are involved in the etiology of Lynch syndrome. Such constitutional mutations
lead to subsequent epigenetic silencing of a neighbouring gene, here, MSH2, causing Lynch syndrome. Thus,
deletions of the last few exons of EPCAM constitute a distinct class of mutations associated with HNPCC.
Worldwide, several investigators have reported families with EPCAM 3’end deletions. The risk of colorectal cancer in
carriers of EPCAM deletions is comparable to situations when patients are MSH2 mutation carriers, and is associated
with high expression levels of EPCAM in colorectal cancer stem cells. A lower risk of endometrial cancer was also
reported. Until now the standard diagnostic tests for Lynch syndrome have contained analyses such as
immunohistochemistry and tests for microsatellite instability of mismatch repair genes. The identification of EPCAM
deletions or larger EPCAM-MSH2 deletions should be included in routine mutation screening, as this has
implications for cancer predisposition.
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Lynch Syndrome (LS; or previously HNPCC – Hereditary
Non-Polyposis Colorectal Cancer) is one of the most com-
mon cancer susceptibility syndromes, which accounts for
approximately 1-4% of all colon cancer cases [1]. It is
characterized by an early onset of ColoRectal Cancer
(CRC) and increased risk for the occurrence of several
extra-colonic malignancies, in particular endometrial can-
cer [2]. In the largest published series 3, 1% of colorectal
cases have been familiar to LS [3]. HNPCC is caused by
inactivating germline mutations in the MisMatch Repair
(MMR) system genes (mainly MSH2, MLH1, MSH6, but
also PMS2) [4]. According to data from NCBI base MLH1
and MSH2 mutations account for about 90% of all muta-
tions connected with Lynch syndrome; MHS6 accounts
for 7-10% and PMS2 is found in less than 5% of these al-
terations. According to recent studies there is another* Correspondence: k.tutlewska@wp.pl
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reproduction in any medium, provided the or1-3% of LS patients within the Dutch and German popula-
tions) and this is the EPCAM gene (Figure 1) [5].
Lynch syndrome-associated tumors are usually charac-
terized by DNA mismatch repair deficiency, and result
from a second somatic event which inactivates the
remaining functional mismatch repair gene allele [6,7].
As a consequence of lack of mismatch repair, tumorigen-
esis is promoted by secondary mutations that accumulate
at short repetitive sequences, a phenotype termed “high
level microsatellite instability” (high-MSI).
In other words, a MMR gene defect in one allele gives
susceptibility to further mutations which may affect sec-
ond allele cause lack of mismatch repair function in cell.
This results in an accumulation of mutations in coding
and non-coding microsatellites in such tumors: so-called
“microsatellite instability” (MSI), which is a characteris-
tic feature of more than 95% of LS–associated CRCs [8],
in addition to the loss of expression of the mutated mis-
match repair gene [9]. Carriers of mutations in MLH1,
MSH2 orMSH6 have a 30-80% cumulative risk of develop-
ing colorectal cancer and women have additional 27-71%ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and











Figure 1 The frequency of mismatch repair gene mutations in
Lynch syndrome.
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[2]. The main clinical features are an early age of onset and
the occurrence of multiple tumors.
Appropriate diagnosis of LS may curried out in two
major ways. One of them is to focus on an adequate
family history in all patients visiting a physician. The re-
vised Bethesda guidelines are probably the most com-
mon used criteria for selecting patients with CRC for
further molecular tests [10,11] (Table 1). The other way
is systematic testing for all patients with CRC for loss of
MMR function by means of high level microsatellite
instability in tumor tissue or immunohistochemistry
(ImmunoHistoChemistry, IHC). The advantage of the
immunohistochemistry, is also allowing prediction of
which mismatch repair gene is likely to be affected by a
germline mutation [10]. In our International Hereditary
Cancer Center patients are classified to Lynch syndrome
according to characteristic clinical features or criteria
and pedigrees typical for Lynch syndrome, what isTable 1 Revised Bethesda guidelines for testing
colorectal tumors for microsatellite instability (MSI)
1 Colorectal cancer diagnosed below 50 years of age.
2 Presence of synchronous, metachronous colorectal, or other Lynch
syndrome-associated* tumors, regardless of age.
3 Colorectal cancer with high-MSI*, histology diagnosed in a patient
who is less than 60 years of age.
4 Colorectal cancer diagnosed with one or more first-degree relatives
with Lynch syndrome – associated tumors*, with one of the cancers
being diagnosed under age 50 years.
5 Colorectal cancer diagnosed in two or more first or second degree
relatives with Lynch syndrome-associated tumors* regardless of age
*Lynch syndrome–associated tumors: tumors of the endometrium, small
bowel, or urinary tract; high-MSI = high level microsatellite instability in
tumors refers to changes in two or more of the five NCI-recommended panels
of microsatellite markers.
Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer
[Lynch syndrome] and microsatellite instability (Umar A, Boland CR, Terdiman JP,
et al. (2004).presented by Kladny and Lubinski [12]. An example of a
pedigree of a family with definitive HNPCC and EPCAM
carriers is shown in Figure 2.
In some individuals with Lynch syndrome the MMR
genes mutation search fails. This group is of particular
interest to researchers, who trying to find the genetic
factors causing the disease. In some LS patients it have
been shown that MMR genes methylation cause disease
occurence [13-16]. Some evidence for this came from
studies in which the MLH1 gene was the target of
methylation in germline tissues in HNPCC patients who
were not carriers of a germline MLH1 mutation [17].
Moreover, heritable germline epimutations in MSH2
have been reported as well, in some MMR germline-
mutation-negative LS families [18].
A new mechanism of inactivating MSH2 gene was
therefore predicted. In multiple patients in which LS was
suspected, with no germline mutation found in the MMR
genes, a heterozygous germline deletion was identified
encompassing the polyadenylation site located in the last
two exons [8,9] of the EPCAM gene (OMIM#185535,
formerly known as TACSTD1) [19]. Such deletions disrupt
the 3’ end of the EPCAM gene, leading to transcriptional
read-through of the mutated EPCAM allele and epigenetic
inactivation, and silencing of, its neighbouring gene
MSH2. MSH2 is located 17 kb downstream of EPCAM on
chromosome 2, and causes Lynch syndrome [20]. This
epigenetic inactivation is restricted only to cells expressing
EPCAM, and therefore patients who carry EPCAM dele-
tions show mosaic patterns of MSH2 inactivation that,
compared with carriers of a mutation in MSH2, may lead
to differences in tumor occurrence or spectrum [20].
What is interesting, high expression of EPCAM in colo-
rectal cancer stem cells answers the question of why car-
riers with an EPCAM 3’ end deletion have a substantially
increased risk of colon cancer.
Kempers and colleagues (2011) in their studies esta-
blished different cancer risks associated with EPCAM de-
letions, depending on whether a deletion affects only the
EPCAM gene or both the EPCAM and its neighboring
geneMSH2 (EPCAM-MSH2). These risks were then com-
pared with those for Lynch syndrome carriers of a mu-
tation in MMR genes. This was the first study that
described the cumulative cancer risks and cancer profile
of EPCAM deletion carriers [21]. They reported a low risk
for endometrial cancer in patients with deletions of
EPCAM compared to that with a mutation in an MMR
gene. Of the 194 individuals with an EPCAM mutation in-
cluded in their studies, 16 developed cancers other than
colonic or endometrial [duodenal: n=3; and pancreatic:
n=4; were the most common].
An interesting recent study by Kloor et al. (2011) re-
vealed that concomitant lack of EPCAM and MSH2 pro-
tein expression is a feature highly specific for cancers
del  EPCAM (8-9 exons)
Figure 2 A pedigree familiar to Lynch syndrome. COL, colon cancer; FGT, cancer of the female genital tract; d. - age of death.
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munohistochemistry as a potential analysis tool for the
identification of Lynch syndrome patients with EPCAM
germline deletions [22]. However, there was a problem
with this approach, because EPCAM protein expression
was retained in some cancers from EPCAM mutation
carriers. Investigators have not determined the relation-
ship between EPCAM protein expression status in can-
cers and localization of an EPCAM germline deletion
[22]. This is why Huth et al. (2012) hypothesized that a
second somatic hit (leading to MSH2 inactivation) deter-
mined EPCAM expression in tumor cells. (They ana-
lyzed four carcinomas and two adenomas from EPCAM
deletion carriers for EPCAM protein expression and al-
lelic deletion status of the EPCAM gene [7].
The EPCAM gene
The EPCAM gene (Epithelial Cellular Adhesion Mol-
ecule; alternative name TACSTD1 - Tumor Associated
Calcium Signal TransDucer 1, OMIM#185535) encodes
a carcinoma-associated antigen which is a glycosylated
member of a family that includes at least two type I
membrane proteins [23]. It is located on the short (p)
arm of chromosome 2 at position 21. More precisely,
from base pair 47,596,286 to base pair 47,614,166 on
chromosomes 2.In healthy tissues EPCAM is located in the basolateral
membrane but in cancer tissues this protein is homoge-
neously distributed on the cell surface. EPCAM is not only
implicated in mediating epithelial-specific intercellular ad-
hesion, but also in intracellular signaling, migration, pro-
liferation and differentiation. The extracellular part of
EPCAM contains an epidermal growth factor-like domain
and a presumed thyroglobulin domain. Activation of
EPCAM signaling is mediated by intra-membrane prote-
olysis through which the extracellular domain is shed and
the intracellular domain (EpICD) is released into the cyto-
plasm (Figure 3). Here it becomes part of a large nuclear
complex containing the transcriptional regulators β-
catenin and Lef, both components of the wnt signaling
pathway [2].
It has, therefore, been speculated that EPCAM on normal
epithelia is sequestered and, therefore, much less accessible
to antibodies than EPCAM in cancer tissue, where it is
homogeneously distributed on the cancer cell surface [23].
The antigen EPCAM is presently being used as a tar-
get for immunotherapy treatment of human carcinomas.
Deletions involving the transcription termination sig-
nal of EPCAM are causative in 1% to 2.8% of families
with Lynch syndrome. Other EPCAM alterations that
don’t affect the transcription termination signal cause
autosomal-recessive congenital tufting enteropathy [24].
Figure 3 Schematic representation of signaling pathways involving EPCAM, proposed by Maetzel D et al. (2009) [23]. (a) Cleavage of
EPCAM by TACE and PS-2. (b) EPCAM signalling and possible cross-talk with E-cadherin and Wnt pathways. EPCAM signalling is induced by RIP,
leading to EpICD nuclear translocation in a complex with FHL2 and -catenin. Within the nucleus, the EpICD complex interacts with Lef-1 and
contacts DNA. Upon interference with E-cadherin, EPCAM may increase the availability of its interaction partner -catenin in the soluble fraction.
Cross-talk with the Wnt pathway is conceivable at the level of -catenin and Lef-1 interactions with EpICD, and is known for induction of the
EPCAM promoter by Tcf4 (Maetzel D, Denzel S, Mack B, et al., Nature Cell Biology 11, 162 – 171, 2009).
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EPCAM deletions cause MSH2 gene silencing by a
mechanism known as promoter hypermethylation. Add-
itional methyl groups attached to the MSH2 promoter
reduce the expression of the MSH2 gene, which means
that less protein is produced in epithelial cells. The
MSH2 protein plays an essential role in repairing mis-
takes in DNA, so loss of this protein prevents proper
DNA repair and mistakes accumulate as the cells con-
tinue to divide. These mistakes can lead to uncontrolled
cell growth and an increased risk of cancer. Lack of
EPCAM immunostaining in MSH2-negative CRCs is in-
dicative of EPCAM gene alterations, and therefore
Musulen Eva and Blanco Ignacio have recommended
(2013) the performance of EPCAM immunohistochemis-
try before MLPA (Multiplex Ligation-dependent Probe
Amplification) analysis [4].Van der Klift and his group (2005) first reported dele-
tions encompassing the 3’end of EPCAM which did not
affect the open reading frame of MSH2, in a cohort of
LS-suspected patients [25]. Five years later a relationship
between deletion of the 3′ end of EPCAM and inacti-
vation of MSH2 was independently reported by two
groups. Kovacs et al. (2009) detected four different dele-
tions encompassing the last few exons of EPCAM, in
five families with one or more tumors exhibiting micro-
satellite instability and loss of the MSH2 protein [18]. At
the same time, Ligtenberg et al. (2009) detected similar
EPCAM 3′ end deletions in four Dutch families with
colorectal cancer, showing high microsatellite instability
and loss of the MSH2 protein, but in which no muta-
tions in MSH2 were found. Additionally, in these fam-
ilies the deletion co-segregated with the occurrence of
MSH2-deficient tumors and, in addition, was found to
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[19]. What’s more, Ligtenberg's group (2012) noticed that
this transcriptional read-through induced monoallelic
hypermethylation of the MSH2 promoter present on the
same allele as the 3′ end EPCAM deletion. Sequence ana-
lysis defined the deletion breakpoints, with a deletion of
4909 bp denoted 859-1462_*1999del from EPCAM cDNA.
Haplotype analysis suggested that this mutation originated
from a common founder. All six high-MSI tumors from
these families showed methylation of the MSH2 promoter
by methylation-specific PCR and subsequent bisulfite se-
quencing (Table 2). These observations convincingly indi-
cated that deletion of the 3′ end of EPCAM can lead to
inactivation of the MSH2 promoter and, therefore, should
be considered a novel cause of Lynch syndrome [2].Table 2 Characteristics of the EPCAM deletions compiled by K








2 c.491+529_*874del German 2 5-9
3 c.492-509_*13721del Swiss 2 5-9




6 c.555+901_*4492del American 2 6-9
7 c.858+1244_*4562del Dutch 1 8+9







11 c.859-2524_*10762del Hungarian 1 8+9
12 c.859-353_*618del English 1 8+9
13 c.859-670_*530del German 1 8+9
14 c.859-689_*14697del German# 4 8+9
15 c.859-696_*391del Hungarian 1 8+9
16 c.859-1682_*2116del German 1 8+9
17 c.859-1605_*5862del American 1 8+9
18 c.859-645_*10911del American 1 8+9
19 c.423-545_*3903del German 1 4-9
20 c.859-1860_MSH2:
646-254del





22 c.858+2488_*7469del Spanish 2 8+9
23 c.555+894_*14194del Chinese 2 intron5-2.4 kb
upstream of
MSH2;
German# - includes one family from unknown European origin (van der Klift et al., 2Ligtenberg et al. (2009) also analyzed the family reported
by Chan et al. (2006) with heritable MSH2 promoter
methylation and identified a heterozygous deletion of 22.8
kb (EPCAM cDNA, 555+894_+14194del) that segregated
with the disease [19]. The deletion extended from intron 5
of the EPCAM gene to approximately 2.4 kb upstream of
MSH2, encompassing the 3’ end of EPCAM and leaving
the MSH2 promoter intact. The same authors identified
the same mutation in another Chinese family, where there
was no evidence for a founder mutation. Analyses such as
RT-PCR and methylation-specific PCR of tissue samples
from affected individuals showed that methylation of
MSH2 was limited to EPCAM-expressing cells (Table 2).
Huth et al. (2012) reported that lack of EPCAM ex-











4909 6 AluSx/ AluSq Ligtenberg et al., 2009
Niessen et al., 2009
11.660 25 AluSg/ AluSg/x Kuiper et al., 2011
23.829 24 AluSp/AluSg Van der Klift et al., 2005
10.355 12 AluSx/AluSx Kovacs et al., 2009
22.836 32 AluY/AluSc Ligtenberg et al., 2009
13.128 15 AluY/AluSx Kuiper et al., 2011
9963 18 AluSp/AluSx Kuiper et al., 2011
9963 8 AluSp/AluSx Kuiper et al., 2011
10.074 - AluSp/FLAM-C Alu Kuiper et al., 2011
8674 14 AluSp/AluSx Kovacs et al., 2009
14.734 15 AluSp/AluSp Kuiper et al., 2011
2419 3 AluSx/AluSg Kuiper et al., 2011
2648 18 AluSx/AluSg Kuiper et al., 2011
16.834 24 AluSx/AluSx Kuiper et al., 2011
6058 19 AluSx/AluJo Kovacs et al., 2009
5246 13 AluJb/AluSq Kuiper et al., 2011
8879 10 AluJb/AluSq Kuiper et al., 2011
13.004 14 AluSx/AluSx Van der Klift et al., 2005
16.500 7 AluSq/AluJo Kuiper et al., 2011
28.900 3 AluY/AluSx Cabornero et al., 2011
8672 32 AluSp/AluSx Mur et al., 2013
11.600 19 AluSp/AluSp Mur et al., 2013
22.8 kb 6 AluSx/AluSq Ligtenberg et al., 2009
005).
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The differences in EPCAM expression were not related
to the localization of EPCAM germline deletions. There-
fore they hypothesized that a type of second somatic hit,
leading to MSH2 inactivation during tumor develop-
ment, determines EPCAM expression in the tumor cells.
In four out of six tumors, investigators detected lack of
EPCAM expression accompanied by biallelic deletions
affecting the EPCAM gene. In contrast, monoallelic reten-
tion of the EPCAM gene was observed in the remaining
two tumors with retained EPCAM protein expression.
These results indicate that EPCAM expression in tumors
from EPCAM deletion carriers depends on the localiza-
tion of a second somatic hit that inactivates MSH2. These
data demonstrate the lack of EPCAM protein expression
observed in tumors from a combination of a germline mu-
tation and second somatic hit. They also show that hetero-
zygous EPCAM germline deletions are not necessarily
associated with loss of EPCAM expression in tumor tis-
sue. The detection of a somatic mutational event causing
MSH2 inactivation in one of the EPCAM positive tumors,
explains why some tumors from EPCAM deletion carriers
show loss ofMSH2, but retained EPCAM expression [7].
The incidence of EPCAM deletions appeared to vary be-
tween populations and was found to represent at least 1-3%
of the explained Lynch syndrome families. Detailed analysis
of the EPCAM deletions revealed their range of variability
as well as their Alu-repeat-mediated origin as a likely
mechanism for these rearrangements [5]. Indeed, all
EPCAM deletion breakpoints characterized by various au-
thors were located within repetitive Alu elements (Table 2).
Alu elements are a family of Short Interspersed Nuclear
Elements (SINE) found only in primates and comprise
about 10.5% of the human genome [26]. These are mobile
retrotransposable elements that also contain a recombino-
genic motive, leading them to recombinational activity.
However, their mobility and susceptibility to recombin-
ation is presumably tempered by host-defensive methyla-
tion of these CpG-rich elements [26]. Deletions formed
through unequal Alu-mediated homologous recombin-
ation involve a cross-over at regions of shared sequence
identity between two parental Alu elements located in cis
in the same orientation, with loss of the loop of intervening
genomic sequence during the exchange. These deletions
are identifiable by signatory tracts of perfect Alu-derived
sequence identity, overlapping or adjacent to the deletion
breakpoints, such that the deletion junction cannot be
mapped to a precise nucleotide. Perez-Cabornero and col-
leagues (2011) mapped each of the deletion breakpoints to
within short stretches of fused Alu sequences that shared
close homology to their respective parental Alu elements
[27]. This is the first such finding to date and prompted a
revisitation of the role of Alu elements in the causation of
Lynch syndrome.Prevalence of EPCAM deletions
Worldwide, EPCAM deletions were found to be present
in various populations from different geographic origins
[18,28] (Table 2). Their prevalence was found to vary be-
tween these populations, partly because of the presence
of various founder mutations [5], and to account for up
to 10% of the MSH2 inactivating mutations. All Lynch
syndrome-associated tumors from EPCAM deletion car-
riers that were available for testing showed hypermethy-
lation of the MSH2 promoter [13]. Detailed analyses of the
breakpoints of these deletions indicated that they predom-
inantly originate from Alu repeat-mediated recombination
events [2]. A wide variety of different deletions could be
reflected in different recombination events caused by a
high number of Alu repeats spread across this locus [9].
This situation was documented by Grandval et al. [29],
namely EPCAM deletions in three out of seven of their
patients as de novo mutations, which probably reflects
the relatively high Alu repeat-mediated recombination
frequency at this locus [2].
Our unpublished data from the studies of 55 patients
with LS indicates that deletions of 8 and 9 exons of the
EPCAM gene determine 7% of LS cases without MMR
mutation.Tumor spectrum of EPCAM deletions
Constitutional rearrangements affecting the open read-
ing frame of genes typically lead to constitutive inactiva-
tion of these genes, irrespective of the cell type. In
contrast, in EPCAM 3′ end deletion carriers MSH2 in-
activation is cell type-specific, since the epigenetic silen-
cing of MSH2 is restricted to cells in which the EPCAM
locus is active and transcriptional read-through occurs.
The outcome of this is that carriers of EPCAM deletions
show mosaic patterns of MSH2 inactivation. This pheno-
menon involving the inactivation of one of the EPCAM al-
leles might lead to a tumor spectrum that is different from
that of germline mutations directly affectingMSH2 [2].
Some investigators have compared the cancer risk for
carriers of an intragenic MSH2 mutation, a combined
EPCAM-MSH2 deletion, and a deletion of the 3′ end of
EPCAM. The colorectal cancer risk of EPCAM mutation
carriers, as reflected by the mean age at diagnosis and
the cumulative risk by age 70 years, was similar to that
of EPCAM-MSH2 or MSH2 mutation carriers. In con-
trast, the cumulative risk of endometrial cancer by the age
of 70 years was significantly lower for 3′ end EPCAM de-
letion carriers than for combined EPCAM-MSH2 deletion
carriers and MSH2 mutation carriers (Table 3). Import-
antly, the comparison of the tumor risk between the
EPCAM and EPCAM-MSH2 deletion carriers indicates
that the difference in endometrial cancer risk relates to the
mosaic inactivation of MSH2 and not to a constitutive loss
Table 3 Heterozygous inactivation of EPCAM and/or
MSH2 in colorectal and endometrial cancer risk of carriers
of different germline mutations inactivating MSH2,




EPCAM MSH2 Colorectal Endometrial
3’ end EPCAM deletion Yes Mosaic High Low
EPCAM-MSH2 deletion Yes Yes High High
Intragenic MSH2 deletion No Yes High High
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tumors was also observed in several other studies [30].
As mentioned above, the average age at onset, the risk of
colorectal cancer and the tumor phenotype in EPCAM de-
letion carriers are comparable to those carrying a typical
mismatch repair gene mutation in MLH1 or MSH2, where-
as the cumulative risk of endometrial cancer is much lower
[5,20]. In EPCAM deletion carriers there is a relatively low
risk of endometrial cancer, which is the second most
prevalent Lynch syndrome-associated malignancy in car-
riers of a mismatch repair mutation. EPCAM deletion car-
riers will probably be more easily recognized than carriers
of an MSH6 mutation, whose colorectal cancer risk is
lower with a higher age of onset [2].
In the cohort from Grandval et al. (2012), EPCAM de-
letion carriers only developed tumors of the digestive
tract. Their risk to develop colorectal cancer was par-
ticularly high, only two of the 29 deletion carriers aged
over 30 being unaffected [29].
EPCAM founder deletions
A number of founder mutations have been identified in
MMR genes, but only one affecting the EPCAM gene
[19,31]. This 4.9 kb EPCAM founder deletion, thus far
observed by Ligtenberg et al. in seven Dutch families,
was found to be present in nine out of ten additional
families from The Netherlands, but in none of the fam-
ilies from other geographic origins, thus confirming its
founder nature (Table 2) [5]. In 2013, Mur and Pineda
detected two EPCAM deletions: c.858+2568_*4596del
(found in three families) and c.858+2488_*7469del (in
two families; all five were unrelated Spanish LS families).
Furthermore, they describe the EPCAM c.858+2568_
*4596del mutation as the first reported EPCAM founder
mutation in Spain (Table 2) [32].
In addition, six EPCAM deletions were identified in
more than one family originating from Germany (deletions
2 and 14 in Table 2, n = 2 and n = 4, respectively),
Switzerland (deletion 3 in Table 2, n = 2), and the United
States (deletion 6 in Table 2, n = 2) or from multiple origins
(deletions 5 and 10 in Table 2, n = 3) [5].Diagnostics of EPCAM 3’end deletion carriers
Mutational screening of carriers of 3’end deletions of
EPCAM is based on matching the Amsterdam or Be-
thesda criteria and is associated with an MSI phenotype
or loss of MMR protein expression in tumors.
Immunohistochemical analysis of MMR protein ex-
pression is a hallmark of Lynch syndrome diagnostics,
but it cannot distinguish between EPCAM deletion car-
riers and MSH2 mutation carriers [33]. The dependence
of EPCAM expression on both germline and somatic al-
terations explains why EPCAM immunohistochemistry
can yield inconspicuous results in a subset of tumors
from EPCAM deletion carriers, namely if a second som-
atic MSH2 inactivating hit does not affect the EPCAM
gene [7]. Moreover, Huth and his team reported a lack
of EPCAM protein expression in a colorectal adenoma,
suggesting that EPCAM immunohistochemistry may
detect EPCAM deletions already at a precancerous
stage [7].
Germline rearrangements in the EPCAM gene and
MSH2 promoter methylation are detected by using
multiplex ligation-dependent probe amplification (MLPA)
analysis containing probes for a specific region [9,19,32].
Huth et al. (2012) revealed, following MLPA analysis,
biallelic deletions affecting the EPCAM gene in four out
of six analyzed tumors. In the remaining two tumors, no
biallelic EPCAM deletions were observed, and the allelic
profile obtained for the EPCAM gene region was identical
in DNA isolated from tumor tissue and matched blood
samples. All tumors showing biallelic deletions in the
EPCAM gene region were negative for EPCAM protein
expression, while EPCAM protein expression was retained
in the tumors which retained a one normal EPCAM allele.
These scientists also proved that the MLPA technique is
applicable for the detection of heterozygous and homozy-
gous deletions in DNA isolated from paraffin-embedded
tumor tissue (when for example no blood is available) [7].
As a additional method for detecting specified dele-
tions in the EPCAM gene, Ligtenberg and Kuiper (2009)
used long range PCR and real-time quantitative RT-PCR.
For long range PCR across the deletion, in Dutch fam-
ilies, a TAKARA PCR kit was used with primers on ei-
ther side of the deletion. Further, they specified the
deletion by direct-sequencing, using a forward primer in
combination with an internal reverse primer. For the
Chinese families they performed multiple long range
PCRs, which yielded an aberrant amplicon suggestive of
a large deletion mutation [19]. To detect fusion tran-
scripts, a direct RT-PCR reaction or a nested-RT-PCR
was performed [19,21].
Recently, Pritchard and his team from the USA (2012)
notified a comprehensive and cost-effective test called
“ColoSeq” that detects all classes of mutations in Lynch
and polyposis syndrome genes, using solution-based
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Due to this technique they correctly identified 28/28
(100%) pathogenic mutations in MLH1, MSH2, MSH6,
PMS2, EPCAM, APC and MUTYH, including single nu-
cleotide variants (SNVs), small insertions and deletions,
and large copy number variants. These scientists focused
on defining the sensitivity of heterozygous variant detec-
tion because pathogenic mutations in Lynch and polyp-
osis syndromes are almost always heterozygous, except
in the MUTYH gene. There was 100% reproducibility of
mutation detection between independent runs [34]. The
Coloseq assay demonstrated at least exon-level reso-
lution for all large deletions and duplications, which was
comparable or even better than the resolution of trad-
itional approaches to these kind of mutations analysis
such as MLPA, in which exact breakpoints could not be
determined, because they are commonly in Alu or other
repetitive DNA elements [34].Conclusions
Based on previous worldwide results, there is a strong
suggestion that implementation of EPCAM deletion
mapping in routine diagnostics on suspected Lynch syn-
drome families should be considered. Some studies sug-
gest that the frequency of EPCAM deletions as a cause
of Lynch syndrome is up to 30% in patients with
MSH2–negative tumors (from IHC results) or approxi-
mately 20% of LS patients without a mutation in MMR
genes [18,22].
This underlines the importance of EPCAM deletions
in the Lynch syndrome, as it is a more frequent cause of
LS than mutations in PMS2 or MSH6 [33].
The frequent occurrence of somatic deletions affecting
the EPCAM gene as a second hit in tumors from
EPCAM deletion carriers suggests that the localization
of somatic events inactivating mismatch repair genes in
Lynch syndrome is not random, but related to the
underlying germline mutation [7].
In conclusion, EPCAM 3’end deletions are a recurrent
cause of Lynch syndrome, and detection should be
implemented in routine Lynch syndrome diagnostics.
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